-
1 Comment
Assertio Holdings, Inc is currently in a long term downtrend where the price is trading 40.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.6.
Assertio Holdings, Inc's total revenue sank by 49.0% to $30M since the same quarter in the previous year.
Its net income has increased by 87.4% to $-24M since the same quarter in the previous year.
Finally, its free cash flow fell by 176.6% to $-6M since the same quarter in the previous year.
Based on the above factors, Assertio Holdings, Inc gets an overall score of 2/5.
| Industry | Drug Manufacturers - Specialty & Generic |
|---|---|
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US04546C2052 |
| Sector | Healthcare |
| Beta | 0.57 |
|---|---|
| Market Cap | 56M |
| PE Ratio | None |
| Target Price | 2.85 |
| Dividend Yield | None |
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ASRT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
